Literature DB >> 12828577

Cardiocirculatory effects of patent ductus arteriosus in extremely low-birth-weight infants with respiratory distress syndrome.

Senji Shimada1, Takeo Kasai, Atsuki Hoshi, Atsushi Murata, Shoichi Chida.   

Abstract

BACKGROUND: Cardiocirculatory effects of hemodynamically significant patent ductus arteriosus (hsPDA) have not been systematically studied in extremely low-birth-weight (ELBW) infants with respiratory distress syndrome (RDS). The objective of the present study was to evaluate the effects of hsPDA on the left ventricular output (LVO) and organ blood flows in ELBW infants with RDS.
METHODS: Extremely low-birth-weight infants (birth-weight <1000 g) treated with surfactant for RDS were studied by serial Doppler flow examinations. Doppler flow variables in 19 infants in whom hsPDA developed (hsPDA group) were compared with those in 19 infants without hsPDA matched for gestational age, birth-weight, and postnatal age (non-hsPDA group). All infants in the hsPDA group had pharmacologic closure of ductus arteriosus when hsPDA developed.
RESULTS: Before pharmacological closure of PDA, the hsPDA group had significantly higher LVO, lower blood flow volume of the abdominal aorta, and lower mean blood flow velocities in the celiac artery, superior mesenteric artery, and renal artery than the non-hsPDA group. These alterations in the hsPDA group reverted to the levels in the non-hsPDA group after the closure of PDA and had no deleterious effects on the cardiorespiratory status. No significant differences between the groups were found in mean blood flow velocities of the anterior cerebral artery throughout the study period.
CONCLUSION: These results indicate that although LVO is increased, the splanchnic and renal blood flows are decreased when hsPDA develops in ELBW infants with RDS. The effects of these alterations of LVO and organ blood flows on the cardiorespiratory course seem to be minor when early pharmacologic closure of PDA is done.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12828577     DOI: 10.1046/j.1442-200x.2003.01713.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  17 in total

Review 1.  Patent ductus arteriosus: lack of evidence for common treatments.

Authors:  Carl L Bose; Matthew M Laughon
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-11       Impact factor: 5.747

2.  Can lactate levels be used as a marker of patent ductus arteriosus in preterm babies?

Authors:  Nilüfer Okur; Cüneyt Tayman; Mehmet Büyüktiryaki; Gülsüm Kadıoğlu Şimşek; Buse Ozer Bekmez; Nahide Altuğ
Journal:  J Clin Lab Anal       Date:  2018-09-02       Impact factor: 2.352

3.  Superior mesenteric artery blood flow velocities following medical treatment of a patent ductus arteriosus.

Authors:  Toby Debra Yanowitz; Jeff Reese; Maria Gillam-Krakauer; Caitlin M Cochran; Priya Jegatheesan; John Lau; Vy Thao Tran; Michele Walsh; William A Carey; Alan Fujii; Anthony Fabio; Ronald Clyman
Journal:  J Pediatr       Date:  2013-12-08       Impact factor: 4.406

Review 4.  Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration.

Authors:  Sindhu Sivanandan; Ramesh Agarwal
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

Review 5.  The role of the intestinal microcirculation in necrotizing enterocolitis.

Authors:  Daniel J Watkins; Gail E Besner
Journal:  Semin Pediatr Surg       Date:  2013-05       Impact factor: 2.754

6.  A decision aid for considering indomethacin prophylaxis vs. symptomatic treatment of PDA for extreme low birth weight infants.

Authors:  Khalid M Alfaleh; Eman Al Luwaimi; Turki M Alkharfi; Saleh A Al-Alaiyan
Journal:  BMC Pediatr       Date:  2011-09-03       Impact factor: 2.125

7.  Molecular evidence of Ureaplasma urealyticum and Ureaplasma parvum colonization in preterm infants during respiratory distress syndrome.

Authors:  Rosario Cultrera; Silva Seraceni; Rossella Germani; Carlo Contini
Journal:  BMC Infect Dis       Date:  2006-11-21       Impact factor: 3.090

8.  A prospective study of maternal preference for indomethacin prophylaxis versus symptomatic treatment of a patent ductus arteriosus in preterm infants.

Authors:  Khalid AlFaleh; Eman Alluwaimi; Ahlam AlOsaimi; Sheikha Alrajebah; Bashayer AlOtaibi; Fatima AlRasheed; Turki AlKharfi; Bosco Paes
Journal:  BMC Pediatr       Date:  2015-04-22       Impact factor: 2.125

Review 9.  Patent ductus arteriosus in preterm infants: do we have the right answers?

Authors:  Hesham Abdel-Hady; Nehad Nasef; Abd Elazeez Shabaan; Islam Nour
Journal:  Biomed Res Int       Date:  2013-12-23       Impact factor: 3.411

10.  Persistent Ductus Arteriosus in Critically Ill Preterm Infants.

Authors:  Maria Livia Ognean; Oana Boantă; Simona Kovacs; Corina Zgârcea; Raluca Dumitra; Ecaterina Olariu; Doina Andreicuţ
Journal:  J Crit Care Med (Targu Mures)       Date:  2016-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.